Expert Video - What treatment challenges do elderly patients face in AML?
In this video, acute myeloid leukemia (AML) expert Dr. Jamile Shammo discusses treatment challenges that elderly AML patients may often face. Older patients often have co-morbid conditions such as kidney or heart disease and are more vulnerable to AML than younger patients. Tolerability to induction chemotherapy may be less among elderly patients than younger patients. Some chemotherapeutic agents such as anthracyclines may present with cardiac toxicity in patients with heart disease. Elderly patients may have challenges due to both AML and MDS cytogenetic abnormalities. Elderly patients may have resistance to chemotherapy and experience adverse drug tolerability and may also be more vulnerable to infectious complications. Combination therapy such as azacitidine and venetoclax are given to elderly patients because of better tolerability and response rates to treatment in AML.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by educational grants from AbbVie, Acceleron, Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.